Therapeutic Antibody Primer

Emily BurkeBiologics, Biotech Basics, Cancer, Clinical Trials, Drug Development, Drug Targets, Easily Confused, Mechanism of Action, Monoclonal Antibodies, Small Molecule Drugs

Basics & Innovations Monoclonal antibody (mAb) therapeutics burst onto the healthcare scene 20 years ago, and today they remain one of the most versatile and effective therapeutics available. The tried and true mAbs are still in high demand, and we suspect this first wave of derivative products clamoring their way through the pipeline will be equally as successful. In this WEEKLY, we’ll … Read More

The Tight Junction’s Function

Emily BurkeBiologics, Biotech Basics, Cancer, Clinical Trials, Drug Development, Drug Targets, Mechanism of Action, Monoclonal Antibodies, The WEEKLY

A Pathway Lies In The Bridge Between Cells Most of us remember from high school biology that cells are the basic building blocks of all living things. Cells join together to form tissues and organs such as hearts, lungs, and livers, which work together to create a functioning human. An adult human body contains trillions of cells, and these cells must … Read More

The Long And Short Of AMD

Emily BurkeBiologics, Clinical Trials, Deoxyribonucleic Acid (DNA), Drug Development, Drug Targets, Genetics, Mechanism of Action, Monoclonal Antibodies, Term of the Week, The WEEKLY

A Spotlight On One Of The Most Prevalent Eye Diseases It’s easy to take our ability to see for granted. On a day-to-day basis, we rely on vision to process information and to navigate the world without giving it a second thought. For the millions of people affected by eye disease, vision loss, and blindness, impaired vision is a daily reality … Read More

Next-Generation CAR-T

Emily BurkeBiologics, Business of Biotech, Cancer, Clinical Trials, Drug Development, Drug Targets, Genomics, Mechanism of Action, Monoclonal Antibodies, The WEEKLY

The Race Is On Our last WEEKLY—Hacking the Immune Response—unveiled the science behind CAR-T and TCR, two immunotherapies under the microscope of the mainstream press. The well-deserved media attention highlights the ability of these “living drugs” to recognize and obliterate cancers. With all of the early phase clinical success, a few challenges have popped up: • Safety: CAR-T and TCR can … Read More

RNAi Crashes The PCSK9 Party

Emily BurkeBiologics, Business of Biotech, Cardiovascular Disease, Clinical Trials, Drug Approvals, Drug Development, Drug Targets, FDA, Mechanism of Action, Monoclonal Antibodies, Ribonucleic Acid (RNA), The WEEKLY

Newest Hopeful In Cholesterol Lowering Landscape Just weeks after the biotech world celebrated the approvals of two new cholesterol-lowering PCSK9 inhibitors, Regeneron/Sanofi’s Praulent and Amgen’s Repatha, a potential future rival arrived in style. Enter Alnylam (Cambridge, MA), with its RNAi-based experimental drug ALN-PSCsc, which just completed Phase I with positive results. What makes PCSK9 inhibitors so hot, and why are the new cholesterol drugs on the market … Read More

It’s A Great Time To Be In Biotech

Emily BurkeBiologics, Biotech Basics, Cancer, Clinical Trials, Drug Approvals, Drug Development, Drug Targets, FDA, Genomics, HIV, Mechanism of Action, Monoclonal Antibodies, The WEEKLY

It’s a great time to be in biotech—new therapeutics are breaking ground faster than we can say “monoclonal antibody” and the technologies behind them are heavy with promise and potential. Our mission is to keep your industry knowledge up to date and the WEEKLY is here to give you a smart primer on the basics. Below we have outlined several … Read More

The Bispecific Antibody: A Lethal Hybrid

Emily BurkeBiologics, Cancer, Drug Approvals, Drug Targets, FDA, Mechanism of Action, Monoclonal Antibodies, Term of the Week, The WEEKLY

Amgen’s acute lymphoblastic leukemia treatment, Blincyto, coasted past the FDA bottleneck ahead of schedule, gaining approval earlier this month as a “first of its kind” immunotherapy. The FDA designated Blincyto as a breakthrough therapy and an orphan product on top of granting a priority review, thus propelling the bispecific antibody (BsAb) to the market five months early. The swift approval … Read More

12 Biotech Concepts Everyone Should Know

Emily BurkeBiologics, Biotech Basics, Business of Biotech, Cancer, Cardiovascular Disease, Clinical Trials, Diabetes, Diagnostics, Drug Approvals, Drug Development, Drug Targets, Ebola, FDA, Genetics, Mechanism of Action, Monoclonal Antibodies, Orphan Disease, Orphan Drugs, Small Molecule Drugs, The WEEKLY

Our mission here at WEEKLY is to keep your industry knowledge up to date. We will be off Thursday, roasting our turkeys and reminding ourselves that it is not the amino acid tryptophan that makes us drowsy after a Thanksgiving feast—it is the massive carbohydrate intake! Whether you are awaiting a Thanksgiving holiday or it is business as usual, we … Read More

Pioneers In The Land Of Small Proteins

Emily BurkeBiologics, Biotech Basics, Business of Biotech, Clinical Trials, Drug Development, Drug Targets, Mechanism of Action, Monoclonal Antibodies, The WEEKLY

We continue last week’s trek into the IPO wilderness to explore the technology of Molecular Partners (Zurich, Switzerland). What they are in search of is a new class of small protein therapeutics, referred to by their acronym: DARPins. DARPins inherently share some of the same advantages monoclonal antibodies (mAbs) have over small molecule drugs. DARPins go a step further and offer possible … Read More

Sculpting A Better Life For Sickle Cell Patients

Emily BurkeBiologics, Clinical Trials, Cocktail Fodder, Drug Development, Drug Targets, Easily Confused, FDA, Genetics, Mechanism of Action, Monoclonal Antibodies, Orphan Disease, Orphan Drugs, Small Molecule Drugs, The WEEKLY

With the recent announcement of two new biologics in Phase I studies for Sickle Cell Disease (SCD), WEEKLY takes a closer look at the treatments for this autosomal recessive disease, afflicting approximately 100,000 Americans and 25 million globally. Sickle cell anemia is caused by an SNP in the beta globin gene, which codes for hemoglobin—an oxygen-binding protein in red blood … Read More

Matters Of The Heart

Emily BurkeCardiovascular Disease, Clinical Trials, Drug Development, Drug Targets, Easily Confused, Mechanism of Action, Monoclonal Antibodies, The WEEKLY

In a picture perfect game of drug development, Novartis heartily delivered this week with LCZ696. Also propelling the world of cardiovascular disease treatments into high gear is a promising cholesterol therapeutic by Sanofi and Regeneron called alirocumab. Last week, Novartis released a heart failure drug called LCZ696, along with the data behind their highly successful Phase III trial. Novartis is hopeful, … Read More